<DOC>
	<DOC>NCT02521233</DOC>
	<brief_summary>The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the essential hypertension control.</brief_summary>
	<brief_title>Efficacy and Safety of Candesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<mesh_term>Chlorthalidone</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>Signed Consent of the patient; Participants with decompensated essential hypertension, classified into stage 1 (with high or very high cardiovascular risk), stage 2 or stage 3 according to the Brazilian Society of Cardiology (2010), who have never been treated and have indication for drug combination treatment. Obs: The diagnosis may be established by previous evaluation of two blood pressure measures â‰¥ 140/90 mmHg, with two months difference between measurements Patients with any clinically significant disease that in the investigator is opinion can not participate in the study; Secondary hypertension diagnosis or blood pressure above 190x100 mmHg in the screening/randomization visit; Morbid obesity or immunocompromised patients; Participants with greater than 10 mmHg difference in the measurements of systolic or diastolic blood pressure between the two arms; Participants who do not have the two upper limbs; Participants with important electrocardiographic changes; Creatinine clearance less than 60 mL /min; History of hypertensive emergencies and cardiovascular and / or moderate to severe cerebrovascular events in the past 6 months; Microalbuminuria in urine sample greater than 30 mg/g; Patients with history of hypersensitivity to any of the formula compounds; Pregnancy or risk of pregnancy and lactating patients; Participation in clinical trial in the year prior to this study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>